Cholangiocarcinoma;miR-590;SIP1;Epithelial-mesenchymal transition(EMT)  , , , ,"/> miR-590靶向SIP1抑制胆管癌细胞上皮间充质转化的实验研究

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (9): 785-789.

• 论著 • 上一篇    下一篇

miR-590靶向SIP1抑制胆管癌细胞上皮间充质转化的实验研究

  

  1. 1  257335  山东东营  东营市第二人民医院质控科

    2  257335  东营市第二人民医院肿瘤科

    3  100084  清华大学药学院

  • 收稿日期:2018-07-09 修回日期:2018-08-07 出版日期:2018-09-30 发布日期:2018-11-28

miR-590 targeting SIP1 inhibits epithelial-mesenchymal transition in cholangiocarcinoma cells

  1. Quality Control Department, Dongying Second People’s Hospital,Dongying 257335,China

  • Received:2018-07-09 Revised:2018-08-07 Online:2018-09-30 Published:2018-11-28

摘要: 目的 探讨miR-590在胆管癌细胞上皮间充质转化(EMT)中的作用及可能机制。方法 采用荧光定量PCR(QPCR)检测人正常肝内胆管上皮细胞系HIBEC以及人胆管癌细胞系HUCCT1、HCCC-9810、RBE中miR-590的表达情况。双荧光素酶报告试验评价miR-590对SIP1的靶向调控作用。向HUCCT1细胞转染miR-590 mimics(转染组)和无义核苷酸序列(NC组),Western blotting 检测两组EMT相关蛋白的表达。向HUCCT1细胞转染SIP1 siRNA,Western blotting 检测干扰SIP1后EMT相关蛋白的表达。结果 HUCCT1、HCCC-9810、RBE细胞系中miR-590水平分别为0.37±0.084、0.31±0.071和0.53±0.089,显著低于人正常肝内胆管上皮细胞系HIBEC的1.12±0.201,差异具有统计学意义(P<0.05)。miR-590可抑制野生型SIP1 3’UTR报告基因载体的荧光素酶活性,而对突变型SIP1 3’UTR-MUT的荧光素酶活性无影响。转染miR-590 mimics可以下调HUCCT1细胞中Vimentin、N-cadherin、ZEB1、ETS1、SNAIL1及TWIST1蛋白表达,上调E-cadherin蛋白表达。SIP1沉默能上调上皮标志物E-cadherin蛋白表达,并下调间充质蛋白Vimentin和N-cadherin蛋白表达。结论 miR-590通过靶向SIP13’-UTR阻断其翻译,最终抑制胆管癌细胞上皮间充质转化。

关键词: 胆管癌, miR-590, SIP1, 上皮间充质转化

Abstract:

Objective To investigate the role and possible mechanism of miR-590 in epithelial-mesenchymal transition (EMT) of cholangiocarcinoma cells. Methods  Fluorescence quantitative PCR (QPCR) was used to detect the expression of miR-590 in human normal intrahepatic bile duct epithelial cell line HIBEC, human cholangiocarcinoma cell line HUCCT1, HCCC-9810 and RBE. Dual luciferase reporter assay was used to evaluate the regulatory effect of miR-590 on SIP1. MiR-590 mimics (transfected group) and nonsense nucleic aicd sequence (NC group) were transfected into HUCCT1 cells, and Western blotting was used to detect the expression of EMT related protein in two groups. SIP1 siRNA was transfected into HUCCT1 cells and Western blotting was used to detect EMT related protein expression after interfering SIP1. Results The expression levels of miR-590 in HUCCT1, HCCC-9810 and RBE cell lines were 0.37±0.084,0.31±0.071 and 0.53±0.089, which was significantly lower than that of normal intrahepatic bile duct epithelial cell line HIBEC (1.12±0.201), and the difference was statistically significant (P<0.05). MiR-590 mimics significantly reduced luciferase expression in the psiCHECK2-SIP1-3’UTR group (0.37±0.041, P<0.001),while not affecting the expression of the psiCHECK2-SIP1-3’UTR-MUT group (1.21±0.211, P>0.05). Overexpressed of miR-590 could down-regulated the mesenchymal proteins Vimentin, N-cadherin, ZEB1, ETS1, SNAIL1, TWIST1 and up-regulated the epithelial marker E-cadherin. SIP1 silencing could up-regulate the expression of E-cadherin protein and down-regulate the expression of Vimentin and N-cadherin protein. Conclusion MiR-590 blocked its translation by targeting SIP1-3’UTR and ultimately inhibited epithelial mesenchymal transition of cholangiocarcinoma cells.

Key words:

Cholangiocarcinoma;miR-590;SIP1;Epithelial-mesenchymal transition(EMT)  ')">"> Cholangiocarcinoma;miR-590;SIP1;Epithelial-mesenchymal transition(EMT)  ,  ,  ,  

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 刘锦;李贵新;马传香. 恶性黑色素瘤腹腔转移1例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2] 石 玮1,华海清2,王兴华1. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3] 王杰军,李 睿. NCCN成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4] 崔传亮,迟志宏,袁香庆,斯 璐,盛锡楠,郭 军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]

高亚杰1,关小倩1,杨海林1,张 阳2,欧阳学农3,杨建伟4,陈 焰5,徐建明6,赵宣良7,王宝成8,刘文超9,张贺龙10,南克俊11,王湘辉12

. 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[6]  白秀丽1,马振刚1,李际君2. 紫杉醇联合卡培他滨治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(1): 68 .
[7] 徐卫国1,杨小青2,郝世柱1,宋纪宁1,张鹏东1,胡潺潺1,王文雅1. 大肠癌组织中Neuropilin-1的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[8] 许景艳1,欧阳建,章宜芬2,周荣富1,陈 兵1,张启国1,杨永公1,邵小雁1,徐 勇1,关朝阳1. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[9] 张艳玲,邹 岚,肖 红,黄海辉,谭崇富,阮志华,王 希,梁后杰,庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[10] 翟云芝1,陈振东2,秦凤展1. Ezrin和AKT2在大肠癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 25 .